Effects of cannabis use status on cognitive function, in males with schizophrenia

Psychiatry Research

Volumn 206, Issue 2-3, 2013, Pages 158-165

  Rabin, Rachel A ^a,b   Zakzanis, Konstantine K ^a   Daskalakis, Zafiris J ^a,b   George, Tony P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Cannabis; Cannabis dependence; Cognition; Males; Schizophrenia

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CASE CONTROL STUDY; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; HUMAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; SCHIZOPHRENIA; SMOKING;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; YOUNG ADULT;

MLCS; MLOWN;

EID: 85027948118     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.11.019     Document Type: Article

References (85)

1. Aldington, S., Williams, M., Nowitz, M., Weatherall, M., Pritchard, A., McNaughton, A., Robinson, G., Beasley, R., Effects of cannabis on pulmonary structure, function and symptoms. Thorax 62 (2007), 1058–1063.
2. APA, 2000. Treatment of Patients with Schizophrenia: Practice Guidelines for the Treatment of Psychiatric Disorders, Washington, DC.
3. Arseneault, L., Cannon, M., Witton, J., Murray, R.M., Causal association between cannabis and psychosis: examination of the evidence. The British Journal of Psychiatry 184 (2004), 110–117.
4. Barnes, T.R., Mutsatsa, S.H., Hutton, S.B., Watt, H.C., Joyce, E.M., Comorbid substance use and age at onset of schizophrenia. The British Journal of Psychiatry 88 (2006), 237–242.
5. Bechara, A., Damasio, A.R., Damasio, H., Anderson, S.W., Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50 (1994), 7–15.
6. Bechara, A., Tranel, D., Damasio, H., Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 123 (2000), 2189–2202 Pt 11.
7. Benowitz, N.L., Hansson, A., Jacob, P. 3rd, Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39 (2002), 1107–1112.
8. Berman, K.F., Ostrem, J.L., Randolph, C., Gold, J., Goldberg, T.E., Coppola, R., Carson, R.E., Herscovitch, P., Weinberger, D.R., Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Neuropsychologia 33 (1995), 1027–1046.
9. Bersani, G., Orlandi, V., Kotzalidis, G.D., Pancheri, P., Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience 252 (2002), 86–92.
10. Bolla, K.I., Brown, K., Eldreth, D., Tate, K., Cadet, J.L., Dose-related neurocognitive effects of marijuana use. Neurology 59 (2002), 1337–1343.
11. Bowers, M.B. Jr., Mazure, C.M., Nelson, J.C., Jatlow, P.I., Psychotogenic drug use and neuroleptic response. Schizophrenia Bulletin 16 (1990), 81–85.
12. Budney, A.J., Moore, B.A., Vandrey, R.G., Hughes, J.R., The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology 112 (2003), 393–402.
13. Carey, K., Reliability and validity of the time-line follow-back interview among psychiatric outpatients: a preliminary report. Psychology of Addictive Behaviors 11 (1997), 26–33.
14. Cohen, M., Solowij, N., Carr, V., Cannabis, cannabinoids and schizophrenia: integration of the evidence. Australia and New Zealand Journal of Psychiatry 42 (2008), 357–368.
15. Cohen, R.M., Semple, W.E., Gross, M., Nordahl, T.E., DeLisi, L.E., Holcomb, H.H., King, A.C., Morihisa, J.M., Pickar, D., Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences 40 (1987), 2031–2039.
16. Conners, C.K., Conners' Continuous Performance Test II: Computer Program for Windows Technical Guide and Software Manual. 2000, Multi-Health Systems, North Tonawanda, NY.
17. Coulston, C.M., Perdices, M., Tennant, C.C., The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia Research 96 (2007), 169–184.
18. Coulston, C.M., Perdices, M., Tennant, C.C., The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Australia and New Zealand Journal of Psychiatry 41 (2007), 869–884.
19. D'Souza, D.C., Abi-Saab, W.M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T.B., Krystal, J.H., Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57 (2005), 594–608.
20. Davidson, L., McGlashan, T.H., The varied outcomes of schizophrenia. Canadian Journal of Psychiatry 42 (1997), 34–43.
21. Davis, K.L., Kahn, R.S., Ko, G., Davidson, M., Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry 148 (1991), 1474–1486.
22. Delis, D.C., Kramer, J.H., Kaplan, E., Ober, B., California Verbal Learning Test. Second Edition, 2000, The Psychological Corporation., San Antonia, TX (CVLT-II).
23. DeRosse, P., Kaplan, A., Burdick, K.E., Lencz, T., Malhotra, A.K., Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophrenia Research 120 (2010), 95–100.
24. Fergusson, D.M., Horwood, L.J., Swain-Campbell, N.R., Cannabis dependence and psychotic symptoms in young people. Psychological Medicine 33 (2003), 15–21.
25. First, M.B., Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed., 1994, American Psychiatric Association, Washington DC.
26. George, T.P., Vessicchio, J.C., Termine, A., Sahady, D.M., Head, C.A., Pepper, W.T., Kosten, T.R., Wexler, B.E., Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26 (2002), 75–85.
27. Golden, C.J., Stroop color and word test. 1978, Stoelting Co, Wood Dale, IL.
28. Goldman-Rakic, P.S., The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biological Psychiatry 46 (1999), 650–661.
29. Grant, I., Gonzalez, R., Carey, C.L., Natarajan, L., Wolfson, T., Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. Journal of the International Neuropsychological Society 9 (2003), 679–689.
30. Grant, S., Contoreggi, C., London, E.D., Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia 38 (2000), 1180–1187.
31. Green, M.F., What are the functional consequences of neurocognitive deficits in schizophrenia?. American Journal of Psychiatry 153 (1996), 321–330.
32. Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophrenia Bulletin 26 (2000), 119–136.
33. Hajos, N., Katona, I., Naiem, S.S., MacKie, K., Ledent, C., Mody, I., Freund, T.F., Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. European Journal of Neuroscience 12 (2000), 3239–3249.
34. Hancox, R.J., Poulton, R., Ely, M., Welch, D., Taylor, D.R., McLachlan, C.R., Greene, J.M., Moffitt, T.E., Caspi, A., Sears, M.R., Effects of cannabis on lung function: a population-based cohort study. European Respiratory Journal 35 (2010), 42–47.
35. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., Fagerstrom, K.O., The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 86 (1991), 1119–1127.
36. Heaton, R.K., Chelune, G.J., Talley, J.L., et al. Wisconsin Card Sorting Test Manual. 1993, Psychological Assessment Resources, Odessa, FL.
37. Heaton, R.K., Gladsjo, J.A., Palmer, B.W., Kuck, J., Marcotte, T.D., Jeste, D.V., Stability and course of neuropsychological deficits in schizophrenia. Archives of General Psychiatry 58 (2001), 24–32.
38. Heinrichs, R.W., Zakzanis, K.K., Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12 (1998), 426–445.
39. Herkenham, M., Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Research Monograph 112 (1991), 129–145.
40. Hershey, T., Craft, S., Glauser, T.A., Hale, S., Short-term and long-term memory in early temporal lobe dysfunction. Neuropsychology 12 (1998), 52–64.
41. Hughes, J.R., Rose, G.L., Callas, P.W., Do former smokers respond to nicotine differently from never smokers? A pilot study. Nicotine and Tobacco Research 2 (2000), 255–262.
42. Jacobsen, L.K., Mencl, W.E., Westerveld, M., Pugh, K.R., Impact of cannabis use on brain function in adolescents. Annals of the New York Academy of Sciences 1021 (2004), 384–390.
43. Jockers-Scherubl, M.C., Wolf, T., Radzei, N., Schlattmann, P., Rentzsch, J., Gomez-Carrillo de Castro, A., Kuhl, K.P., Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 (2007), 1054–1063.
44. Johns, A., Psychiatric effects of cannabis. British Journal of Psychiatry 178 (2001), 116–122.
45. Joyce, E.M., Roiser, J.P., Cognitive heterogeneity in schizophrenia. Current Opinion in Psychiatry 20 (2007), 268–272.
46. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bulletin 13 (1987), 261–276.
47. Kim, D., Thayer, S.A., Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. The Journal of Neuroscience, 21, 2001 RC146.
48. Kirby, K.N., Petry, N.M., Bickel, W.K., Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. Journal of Experimental Psychology: General 128 (1999), 78–87.
49. Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M., Miettunen, J., Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin, 36, 2009, 1115.
50. Lafayette Instrument Company, 1989. Instruction manual for the 32,025 Grooved Pegboard Test Lafayette Instrument Company, Lafayette, Indiana.
51. Lev-Ran, S., Segev, A., Braw, Y., Levkovitz, Y., Neurocognitive functions of heavy cannabis using schizophrenia patients. European Psychiatry 27 (2012), 365–368.
52. Lewis, D.A., Hashimoto, T., Volk, D.W., Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 6 (2005), 312–324.
53. Lewis, D.A., Moghaddam, B., Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Archives of Neurology 63 (2006), 1372–1376.
54. Lezak, M.D., Howieson, D.B., Loring, D.W., Neuropsychological Assessment. 2004, Oxford University Press.
55. Linszen, D.H., Dingemans, P.M., Lenior, M.E., Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51 (1994), 273–279.
56. Makkos, Z., Fejes, L., Inczedy-Farkas, G., Kassai-Farkas, A., Faludi, G., Lazary, J., Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency. Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011), 212–217.
57. Margolese, H.C., Malchy, L., Negrete, J.C., Tempier, R., Gill, K., Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research 67 (2004), 157–166.
58. Mata, I., Rodriguez-Sanchez, J.M., Pelayo-Teran, J.M., Perez-Iglesias, R., Gonzalez-Blanch, C., Ramirez-Bonilla, M., Martinez-Garcia, O., Vazquez-Barquero, J.L., Crespo-Facorro, B., Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychological Medicine 38 (2008), 1257–1266.
59. Medina, K.L., Hanson, K.L., Schweinsburg, A.D., Cohen-Zion, M., Nagel, B.J., Tapert, S.F., Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. Journal of the International Neuropsychological Society 13 (2007), 807–820.
60. Mobini, S., Body, S., Ho, M.Y., Bradshaw, C.M., Szabadi, E., Deakin, J.F., Anderson, I.M., Effects of lesions of the orbitofrontal cortex on sensitivity to delayed and probabilistic reinforcement. Psychopharmacology (Berl) 160 (2002), 290–298.
61. Nagahama, Y., Fukuyama, H., Yamauchi, H., Matsuzaki, S., Konishi, J., Shibasaki, H., Kimura, J., Cerebral activation during performance of a card sorting test. Brain 119 (1996), 1667–1675 (Part 5).
62. Pope, H.G. Jr., Gruber, A.J., Hudson, J.I., Huestis, M.A., Yurgelun-Todd, D., Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry 58 (2001), 909–915.
63. Rabin, R.A., Zakzanis, K.K., George, T.P., The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophrenia Research 128 (2011), 111–116.
64. Ringen, P.A., Vaskinn, A., Sundet, K., Engh, J.A., Jonsdottir, H., Simonsen, C., Friis, S., Opjordsmoen, S., Melle, I., Andreassen, O.A., Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine 40 (2010), 1337–1347.
65. Sacco, K.A., Termine, A., Seyal, A., Dudas, M.M., Vessicchio, J.C., Krishnan-Sarin, S., Jatlow, P.I., Wexler, B.E., George, T.P., Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Archives of General Psychiatry 62 (2005), 649–659.
66. Schnell, T., Koethe, D., Daumann, J., Gouzoulis-Mayfrank, E., The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) 205 (2009), 45–52.
67. Sevy, S., Burdick, K.E., Visweswaraiah, H., Abdelmessih, S., Lukin, M., Yechiam, E., Bechara, A., Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophrenia Research 92 (2007), 74–84.
68. Shapkin, S.A., Influence of caffeine on physiological and cognitive functions of humans. Human Physiology 28 (2002), 128–133.
69. Sharland, M.J., Gfeller, J.D., A survey of neuropsychologists' beliefs and practices with respect to the assessment of effort. Archives of Clinical Neuropsychology 22 (2007), 213–223.
70. Smith, R.C., Warner-Cohen, J., Matute, M., Butler, E., Kelly, E., Vaidhyanathaswamy, S., Khan, A., Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31 (2006), 637–643.
71. Solowij, N., Michie, P.T., Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. Journal of Psychiatry and Neuroscience 32 (2007), 30–52.
72. Solowij, N., Stephens, R.S., Roffman, R.A., Babor, T., Kadden, R., Miller, M., Christiansen, K., McRee, B., Vendetti, J., Cognitive functioning of long-term heavy cannabis users seeking treatment. The Jouranl of the American Medical Association 287 (2002), 1123–1131.
73. Spaulding, W.D., Reed, D., Poland, J., Storzbach, D.M., Cognitive deficits in psychotic disorders. Yudofsky, P.W.C.S.C., (eds.) Cognitive rehabilitation for neuropsychiatric disorders, 1996, American Psychiatric Press, Washington, DC.
74. Tombaugh, T.N., The Test of Memory Malingering (TOMM): normative data from cognitively intact and cognitively impaired individuals. Psychological Assessment 9 (1997), 260–268.
75. van Dijk, D., Koeter, M.W., Hijman, R., Kahn, R.S., van den Brink, W., Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophrenia Research 137 (2012), 50–57.
76. Verrico, C.D., Jentsch, J.D., Roth, R.H., Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 49 (2003), 61–66.
77. Wechsler, D., Wechsler Test of Adult Reading. 2001, Psychological Corporation, San Antonio.
78. Wechsler, D.A., Wechsler Adult Intelligence Scale. 3rd ed., 1997, The Psychological Corporation., San Antonio, TX III ed.
79. Williams, G.V., Goldman-Rakic, P.S., Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376 (1995), 572–575.
80. Wilson, R.I., Nicoll, R.A., Endocannabinoid signaling in the brain. Science 296 (2002), 678–682.
81. Wing, V.C., Bacher, I., Sacco, K.A., George, T.P., Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Research 188 (2011), 320–326.
82. Wing, V.C., Moss, T.G., Rabin, R.A., George, T.P., Effects of cigarette smoking status on delay discounting in schizophrenia and healthy controls. Addictive Behaviors 37 (2012), 67–72.
83. Woods, S.W., Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64 (2003), 663–667.
84. Yang, C.R., Seamans, J.K., Gorelova, N., Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21 (1999), 161–194.
85. Yucel, M., Bora, E., Lubman, D.I., Solowij, N., Brewer, W.J., Cotton, S.M., Conus, P., Takagi, M.J., Fornito, A., Wood, S.J., McGorry, P.D., Pantelis, C., The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38 (2012), 316–330.